1FW

AUG 1 0 2004

Hard the Rangework Re	. duction Act of 1995, no person		PTO/SB/21 (01-03) Approved for use through 04/30/2003. OMB 0651-0031 t and Trademark Office; U.S. DEPARTMENT OF COMMERCE on of information unless it displays a valid OMB control number.		
OEMAN PADERWORK RE	duction Act of 1995. No betso	Application Number	10/651,828		
TRANSMITTAL		Filing Date	08/28/2003		
FORM		First Named Inventor	ZOLOTUKHIN		
(to be used for all correspo	ndence after initial filing)	Art Unit	1632		
(in the second s		Examiner Name			
Total Number of Pages in T	his Submission 89	Attorney Docket Number	5853-251		
	ENC	LOSURES (Check all that	apply)		
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority		are believed necessary, but please	After Allowance Communication to Group  Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter Other Enclosure(s) (please Identify below):		
	SIGNATURE	OF APPLICANT, ATTORNI	EY, OR AGENT		
	AN SENTERFITT A Melson, Registration No				
Date	1/8-	3-04			
	CERTIFIC	CATE OF TRANSMISSION	MAILING		
first class mail in an envelope a		ansmitted to the USPTO or deposited wor Patents, Washington, DC 20231 or 1	ith the United States Postal Service with sufficient postage as is parte:		
Typed or printed	Gregor A Helson				
Signature Date 8-3-04					
This collection of information is	required by 37 CFR 5. The	information is required to obtain or reta	ain a benefit by the public which is to file (and by the USPTO to		

This collection of information is required by 37 CFR. 5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of ZOLOTUKHIN, S.

Application No. 10/651,828

Examiner:

Filed: August 28, 2003

Group Art Unit: 1632

For:

**MODIFIED AAV** 

## **INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR §1.97(b)**

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA

917

Reg. No. 30,577

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the accompanying form PTO/SB/08A are hereby brought to the attention of the Examiner for independent evaluation. The references were cited in the specification of the present application.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Applicant respectfully requests that the listed documents be considered by the Examiner and made of record in the present application and that an initialed copy of form PTO/SB/08A be returned in accordance with MPEP §609.

## Certification

This Statement is being filed within three months of the filing of this application and/or prior to the issuance of the first Office Action for the present application, and this paper is thus submitted in accordance with 37 CFR §1.97(b). In view of this certification, a fee is not required for consideration of these documents. Nevertheless, should a fee be deemed to be due by the Commissioner, such fee should be charged to Deposit Account No. 50-0951.

Dated: 8-3-04

Docket No. 5853-251

Respectfully submitted,

Gregory M. Nelson, Reg. No. 30,577

AKERMAN SENTERFITT

Post Office Box 3188

West Palm Beach, FL 33402-3188

Telephone: (561) 653-5000

PTO/SB/088 (02-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Beautite for form 1449/PTO				Complete if Known		
	10 10 10 11 1440 170			Application Number	10/651,828	
INFORMATION DISCLOSURE				Filing Date	08/28/2003	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	ZOLOTUKHIN	
(Use as many sheets as necessary)				Art Unit	1632	
(Use as many sneets as necessary)			ecessary)	Examiner Name		
Sheet	1	of	1	Attorney Docket Number	5853-251	

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	٠.	Wu et al. Adeno-Associated Virus Vector-Mediated Transgene Integration into Neurons and Other Nondiving Cell Targets. Journal of Virology. July 1998, Vol. 72, No. 7, pages 5919-5926.	
		Wu et al. Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism. Journal of Virology. September 2000, Vol. 74, No. 18, pages 8635-8647.	
		Grifman et al. Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-Associated Virus Capsids. Molecular Therapy. June 2001, Vol. 3, pages 964-975.	
		Girod et al. Genetic Capsid Modifications Allow Efficient Re-Targeting of Adeno-Associated Virus Type-2. Nature Medicine. September 1999, Vol. 5, pages 1052-1056.	
		Xie et al. The Atomic Structure of Adeno-Associated Virus (AAV-2), A Vector for Human Gene Therapy. Proceedings of the National Academy of Sciences. August 2002, Vol. 99, No. 16, pages 10405-10410.	
·		Rabinowitz et al. Building a Better Vector: The Manipulation of AAV Virions. Virology. 2000, Vol. 278, pages :301-308.	
		Monahan et al. AAV Vectors: Is Clinical Success on the Horizon? Gene Therapy. 2000, Vol. 7, pages 24-30.	
		He et al., A Simplified System for Generating Recombinant Adenoviruses. Proceedings of the National Academy of Sciences. March 1998, Vol. 95, pages 2509-2514.	
		Xiao et al. Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus. Journal of Virology. March 1998, Vol. 72, No. 3, pages 2224-2232.	
		Davidson et al. Recombinant Adeno-Associated Virus Type 2, 4 and 5 Vectors: Transduction of Variant Cell Types and Regions in the Mammalian Central Nervous System. Proceedings of the National Academy of Sciences. Vol. 97, No. 7, pages 3428-3432.	-

Examiner	 Date	
Signature	Considered	

<sup>&</sup>quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.